Bronchiectasis is having a moment in pulmonary medicine. After many years of research and patient data, our understanding of bronchiectasis has finally reached a point where the future of bronchiectasis treatment is ready to be considered.

In this episode, rare lung disease expert Dr. Marion Wencker joins host Elizabeth Estes to explain why bronchiectasis finds itself in a similar position to where idiopathic pulmonary fibrosis (IPF) was 10 years ago. What lessons can the pulmonology community learn from its experience treating IPF? How will those insights, AI, and emerging therapies shape the future of treating bronchiectasis?

Listen to the conversation on The Lung Lab podcast, brought to you by the Open Source Imaging Consortium (OSIC), a show that explores how we are redefining rare and progressive lung disease.

For more information on the Open Source Imaging Consortium (OSIC), visit https://osicild.org/ .

Dr. Lisa Lancaster is one of pulmonology's brightest stars. She's both the Director of the Interstitial Lung Disease (ILD) Program at Vanderbilt University and Chief Medical Officer at Endeavor Biometrics. A pulmonologist with over 25 years of experience and 85 clinical trials behind her, she's one of the most respected voices in interstitial lung disease.

In this episode, Dr. Lancaster sits down with our host Elizabeth Estes to discuss the long and winding road many lung disease patients often face on their way to diagnosis. She shares her perspective on the emotional challenges of delivering life-changing news, the promise of emerging therapies, and the future of ILD treatment she hopes to see.

Listen to the conversation on The Lung Lab podcast, brought to you by the Open Source Imaging Consortium (OSIC), a show that explores how we are redefining rare and progressive lung disease.

For more information on the Open Source Imaging Consortium (OSIC), visit https://osicild.org.